+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 28 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating treatments for germinal center B-cell-like diffuse large B-cell lymphoma GCB DLBCL, a fast-growing blood cancer affecting immature B-cells. The study aims to determine if more people respond to zilovertamab vedotin MK-2140 combined with R-CHP compared to polatuzumab vedotin combined with R-CHP. This is a phase 2 randomized study focused on participants who have not been treated before and have the GCB subtype of DLBCL. Participants will be randomly assigned to receive either zilovertamab vedotin plus cyclophosphamide, doxorubicin, rituximab or its biosimilar R-CHP, or polatuzumab vedotin plus R-CHP. These drugs are given by intravenous infusion on Day 1 of each 3-week cycle for up to 6 cycles, about 4 months. Additionally, participants take prednisone or prednisolone tablets daily on Days 1 to 5 of each cycle. Those with high-risk DLBCL may receive 2 extra cycles of rituximab or its biosimilar. Throughout the study, participants undergo assessments including PET scans to monitor cancer response, and various health evaluations. Researchers measure complete response rate at the end of treatment, progression-free survival, overall survival, event-free survival, and quality of life using standardized tools. Safety is monitored by tracking adverse events and treatment tolerability. The study lasts up to several years with follow-up for long-term outcomes.

Age: 18Years +All GendersPhase 2
148 locations
E

Actively Recruiting

Researchers are evaluating BRX011, an oral medication taken once daily, for adults with geographic atrophy secondary to age-related macular degeneration. This phase 12 study aims to assess both the safety and effectiveness of BRX011 compared to a placebo over nearly two years. The study focuses on how well the treatment slows the progression of geographic atrophy. Participants will be randomly assigned to receive either BRX011 capsules or placebo capsules daily. The study lasts 96 weeks and includes multiple visits to monitor health and treatment response. Safety is closely monitored with regular checks including vital signs, lab tests, eye exams, and imaging to detect any adverse effects. During the study, participants will undergo evaluations such as visual acuity testing and imaging of the eye to measure changes in geographic atrophy area. Researchers will track the annual rate of change in the square root of the geographic atrophy area as the primary outcome. Secondary measures include changes in vision under low light and best-corrected visual acuity. Participant well-being is monitored throughout, and the study is sponsored by Biojiva LLC.

Age: 55Years +All GendersPhase 1Phase 2
17 locations
O

Actively Recruiting

Researchers are investigating the long-term safety and immune response to olipudase alfa therapy in pediatric patients under 2 years old with acid sphingomyelinase deficiency ASMD, also known as Niemann-Pick Diseases. This is a US-based, multicenter, open-label observational study collecting real-world data while patients receive routine clinical care. Some additional tests may be done beyond standard care to meet study goals, but treatment decisions are not affected by study participation. Participants are observed while receiving olipudase alfa as prescribed by their doctors, with no treatment provided by the study itself. The study spans up to 5 years, including up to 4 years for enrolling patients and a follow-up period ranging from 1 to 3 years per participant. The study design allows enrollment without requiring travel to study sites. During the study, researchers will monitor adverse events, serious adverse events, and specific immune reactions related to olipudase alfa over a 3-year period. They will also measure anti-drug antibodies and assess lab results and vital signs. Participation involves data collection from medical records and additional assessments to evaluate treatment safety and immune response over time.

Age: 0 - 2YearsAll Genders
6 locations
E

Actively Recruiting

Researchers are evaluating UBT251, a new medication, in adults with type 2 diabetes to determine its effectiveness and safety. The study compares UBT251 to a placebo and also includes a comparison to semaglutide, an existing treatment for type 2 diabetes. The trial is designed as a phase 2 study to find the appropriate dose and assess treatment impact on blood sugar control. Participants will be randomly assigned to one of four groups receiving UBT251, UBT251 placebo, semaglutide, or semaglutide placebo. Each participant will receive their assigned treatment once weekly by subcutaneous injection. The study includes a treatment period lasting up to 40 weeks, with evaluations at various points including weeks 16, 28, and 40. Throughout the study, participants will undergo regular assessments such as measuring glycated hemoglobin HbA1c to track blood sugar levels, body weight, insulin resistance, blood pressure, cholesterol, and kidney function. Safety will be monitored by recording treatment-emergent adverse events up to 46 weeks. The total participation time covers baseline, treatment, and follow-up visits to evaluate the study outcomes comprehensively.

Age: 18Years - 75YearsAll GendersPhase 2
70 locations
E

Actively Recruiting

Researchers are evaluating whether a combination of elranatamab, daratumumab, and lenalidomide provides better clinical benefits compared to a combination of daratumumab, bortezomib, lenalidomide, and dexamethasone in people newly diagnosed with multiple myeloma who cannot have a transplant. This phase 3 study includes two parts the first focuses on safety, tolerability, and dose finding for elranatamab combinations, while the second compares treatment effectiveness and progression outcomes between the two combination therapies. Participants receive different drug combinations depending on the study part and assigned group. Part 1 evaluates elranatamab combined with daratumumab and lenalidomide or elranatamab with lenalidomide alone, focusing on dose levels. Part 2 randomly assigns participants to receive either elranatamab with daratumumab and lenalidomide or the comparator regimen of daratumumab, bortezomib, lenalidomide, and dexamethasone. During the study, participants undergo regular assessments to monitor safety, treatment response, and disease progression, including measuring minimal residual disease negative complete response and progression-free survival. Researchers also track overall survival, adverse events, lab results, drug pharmacokinetics, and quality of life over an extended follow-up lasting up to approximately eight years after randomization.

Age: 18Years +All GendersPhase 3
180 locations
R

Actively Recruiting

This study aims to collect prospective safety and effectiveness data for the C-Brace System, a microprocessor-controlled knee ankle foot orthosis, following standard care practices. The research focuses on patients with lower extremity pareses who are fitted with the C-Brace device. The goal is to better understand how the C-Brace influences walking speed, balance, risk of falling, and confidence in balance over time. The C-Brace is a custom-made device with thigh, calf, and foot components connected by an ankle joint or spring element. It uses sensors to continuously monitor knee joint movement and walking phases, adjusting hydraulic resistance and knee motion accordingly. Patients enrolled in the registry will undergo baseline evaluation, fitting, training or therapy sessions, and follow-up visits at 6, 12, 24, and 36 months after fitting. Participants will be assessed through various tests including timed walk tests, balance confidence scores, and mobility assessments at different intervals. The study also tracks falls related to device use and changes in activity levels with an activity tracker. Data collected will help characterize the safety and functional impact of the C-Brace over three years of follow-up.

All AgesAll Genders
76 locations
E

Actively Recruiting

Researchers are evaluating how to best recommend chemotherapy for patients with colon cancer based on the presence or absence of circulating tumor DNA ctDNA after surgery. This Phase IIIII trial aims to determine if ctDNA can be used to better identify patients who need adjuvant chemotherapy and to assess optimal chemotherapy regimens for those with detectable ctDNA, as current biomarkers have not been prospectively validated. Participants are assigned to different groups based on their ctDNA status after surgery. Those without detectable ctDNA may undergo serial ctDNA monitoring without treatment or receive shorter chemotherapy regimens. Patients with detectable ctDNA receive more intensive chemotherapy options, including combinations of oxaliplatin, leucovorin, 5-fluorouracil, irinotecan, or capecitabine, administered intravenously or orally over cycles lasting several weeks. The study includes randomization and uses the Signatera test for central ctDNA detection. During the study, participants will undergo regular blood tests for ctDNA status, imaging scans, and clinical assessments. Researchers will track ctDNA positivity over up to 3 years and disease-free survival over up to 5 years. Other measures include overall survival, recurrence rates, and chemotherapy compliance. The total study duration may extend several years with ongoing monitoring to evaluate safety and treatment outcomes.

Age: 18Years +All GendersPhase 2Phase 3
1085 locations
S

Actively Recruiting

Researchers are evaluating the effectiveness of combination antibiotic therapy compared to single antibiotic therapy for adults hospitalized with Staphylococcus aureus bloodstream infections. This study focuses on patients identified as high-risk early in their infection and aims to determine if combination therapy improves outcomes compared to monotherapy. Both methicillin-sensitive and methicillin-resistant bacterial infections are included. The trial is a randomized, crossover Phase 4 study conducted in hospitals. Participants with methicillin-sensitive Staphylococcus aureus bacteremia MSSAB will receive either a single intravenous beta-lactam antibiotic cefazolin or nafcillin or combination therapy including that beta-lactam plus ertapenem. Those with methicillin-resistant Staphylococcus aureus bacteremia MRSAB will be treated with either monotherapy of vancomycin or daptomycin or combination therapy with daptomycin plus ceftaroline. Treatment assignments alternate monthly by hospital. Low-risk patients receive usual care without randomization. During the study, participants will be monitored from enrollment through 30 and 90 days for various outcomes including a desirability of outcome ranking, hospital-free days alive, mortality rates, bacteremia-free days, hospital length of stay, direct hospital costs, antibiotic costs, antibiotic-associated adverse events, and Clostridioides difficile infections. Data from all hospitalized patients with SAB at participating hospitals will be analyzed. The study is expected to complete in January 2029.

Age: 18Years +All GendersPhase 4
13 locations
P

Actively Recruiting

Researchers are evaluating a treatment approach for early-stage hormone-sensitive, HER-2 negative breast cancer with an Oncotype recurrence score of 18 or less. This Phase III trial compares breast conservation surgery with endocrine therapy alone against breast conservation surgery with both radiation and endocrine therapy. The goal is to see if skipping radiation after lumpectomy is not worse in preventing cancer recurrence in the same breast. Participants will be randomly assigned to one of two groups. One group will receive radiation therapy to the breast plus at least five years of endocrine therapy with drugs such as Tamoxifen, Anastrozole, Letrozole, or Exemestane. The other group will receive endocrine therapy only for at least five years without radiation. Radiation must start within 12 weeks of surgery if assigned. Endocrine therapy dosing and schedule are determined by the treating doctor. During the study, participants will have regular follow-ups up to five years to monitor cancer recurrence in the breast and elsewhere, survival, and breast preservation. Assessments will include clinical exams, imaging like mammograms or MRI, and pathology reviews. The main outcome is time to invasive or noninvasive breast tumor recurrence within five years. Some measures will continue through an average of 15 years, including breast conservation rates. Safety and overall health will be monitored throughout and after treatment.

Age: 50Years - 70YearsAll GendersPhase 3
832 locations
S

Actively Recruiting

Researchers are evaluating the safety and effectiveness of the Edwards PASCAL Transcatheter Valve Repair System for patients with severe tricuspid regurgitation who have symptoms and are at an intermediate or higher risk of mortality from tricuspid valve surgery. This randomized, controlled trial compares the device combined with optimal medical therapy OMT to OMT alone. The study is conducted at multiple centers and sponsored by Edwards Lifesciences. Participants are assigned to one of several groups receiving the Edwards PASCAL system plus OMT, OMT alone, or the device with OMT if not eligible for randomization. The transcatheter procedure repairs the tricuspid valve without open surgery. Follow-up visits occur at hospital discharge, 30 days, 3 months, 6 months, and then annually for up to 5 years, allowing long-term monitoring of outcomes. During the study, participants will undergo assessments including quality of life questionnaires, heart imaging, and monitoring for heart failure hospitalizations, mortality, and valve-related events. The main outcome measured at 6 months includes a combination of death, heart device implantation or transplant, valve interventions, hospital admissions for heart failure, and improvement in quality of life. Safety and effectiveness data will be collected throughout the follow-up period of up to 5 years.

Age: 18Years +All GendersPhase Not Applicable
79 locations

1-10 of 28

1